C. Rushton, M. Alcaide, M. Cheung, N. Thomas, et al.
Abstracts Conclusion: DLBCL patients with mutations in relapse‐enriched genes are at a higher risk of treatment failure. Mutations in these genes, specifically hotspot deletions, may have power as biomarkers to identify patients at a high risk of relapse and could inform on the mechanism of acquired resistance to components of R‐CHOP.
U. Vitolo, T.E. Witzig, R.D. Gascoyne, D.W. Scott, et al.
Abstracts Conclusion: Overall, the ROBUST study did not meet the primary endpoint of PFS for R2‐CHOP vs placebo/R‐CHOP in previously untreated patients with ABC‐DLBCL, although a positive trend favoring R2‐CHOP has been observed in advanced stage and higher risk patients. The safety profile of R2‐CHOP was consistent with those of individual medicines, and no new safety signals were identified with the combination.
G.S. Nowakowski, F. Hong, D.W. Scot,t R. Macon, et al.
ADDITION OF LENALIDOMIDE TO R‐CHOP (R2CHOP) IMPROVES OUTCOMES IN NEWLY DIAGNOSED DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL): FIRST REPORT OF ECOG‐ACRIN1412 A RANDOMIZED PHASE 2 US INTERGROUP STUDY OF R2CHOP VS R‐CHOP
Abstracts Conclusion: The addition of lenalidomide to R‐CHOP (R2CHOP) in this phase II study improved PFS in newly diagnosed DLBCL.
P. Langerbeins, J. Bahlo, C. Rhein, H. Gerwin, et al.
Abstracts Conclusion: The results of this study allow to conclude that ibrutinib significantly improves EFS, PFS and TTNT in patients with treatment‐naïve early stage CLL when compared to placebo. There were no significant differences in adverse events between both study arms.